报告期内，随着国内药品集采政策持续推进，公司部分产品价格下降明显，利润空间收窄。在海外市 场，部分产品面临行业竞争加剧以及关税政策调整等因素，导致公司相关产品在海外市场的销售额与盈 利水平同比下滑。此外，公司基于谨慎性原则，按照《企业会计准则》的相关规定，对相关的应收账 款、存货、商誉等计提了减值损失，对当期净利润产生了负面影响。 格隆汇2月27日丨宣泰医药(688247.SH)公布2025年年度业绩快报，本报告期，公司实现营业总收入 44,649.88万元，同比下降12.73%；归属于母公司所有者的净利润为4,894.63万元，同比下降61.67%，归 属于母公司所有者的扣除非经常性损益的净利润为3,137.69万元，同比下降72.47%。 ...

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 57.65% to 64.71% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company ranging from 45.07 million to 54.08 million yuan for 2025 [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 29.61 million and 35.53 million yuan, reflecting a year-on-year decline of 68.82% to 74.02% [1] Reasons for Decline - The decline in net profit is primarily attributed to: 1. The ongoing implementation of domestic drug procurement policies, which has led to significant price reductions for some products and a narrowing of profit margins [1] 2. Increased competition in overseas markets and adjustments in tariff policies, resulting in a year-on-year decrease in sales and profitability of related products [1] 3. The company has prudently recognized impairment losses on accounts receivable, inventory, goodwill, etc., in accordance with relevant accounting standards, negatively impacting current net profit [1]

Core Viewpoint - The company expects a significant decline in net profit and revenue for the fiscal year 2025 compared to the previous year, primarily due to price reductions in domestic drug procurement policies and increased competition in overseas markets [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 45.07 million and 54.08 million yuan for 2025, representing a decrease of 73.62 million to 82.63 million yuan year-on-year, which corresponds to a decline of 57.65% to 64.71% [1] - The expected operating revenue for 2025 is projected to be between 394 million and 473 million yuan, reflecting a decrease of 39.02 million to 118 million yuan compared to the previous year, equating to a decline of 7.63% to 23.02% [1] Reasons for Decline - The decline in net profit and revenue is attributed to several factors: 1. The ongoing domestic drug procurement policy has led to significant price reductions for some products, narrowing profit margins 2. Increased competition and adjustments in tariff policies in overseas markets have resulted in decreased sales and profitability for related products [1] - The company has also made provisions for impairment losses on accounts receivable, inventory, and goodwill based on prudence principles according to relevant accounting standards, negatively impacting current net profit [1]